RankingsPricing
  1. US-listed companies
  2. NeuBase Therapeutics, Inc.
  3. Raw

NeuBase Therapeutics, Inc.NBSE

Market cap
$1.41M
P/E ratio
SummaryFinancials
Back to summarized table
Sep 30,
2011		Sep 30,
2012		Sep 30,
2013		Sep 30,
2014		Sep 30,
2015		Sep 30,
2016		Sep 30,
2017		Sep 30,
2018		Sep 30,
2019		Sep 30,
2020		Sep 30,
2021		Sep 30,
2022
Net loss-5,101,519-1,454,884-5,652,488-9,130,664-15,197,865-25,766,198-23,810,996-13,236,900-26,958,247-17,384,520-25,409,301-33,776,450
Stock-based compensation679,301122431877,75110543
Research and development, Vera acquisition----------3-
Fair Value Adjustment of Warrants--------492,889453,808-950,151-
Depreciation and amortization----1111128,372280,463403,043767,302
Loss on marketable securities-----------25,012-30
Loss on disposal of fixed assets-------1,349-17,814--3,230-31,853-11,439
Equity in losses on equity method investment----10,643-103,143-----262,861-224,534-415,747
Gain on sale of intellectual property-------460,383--316,724-
Amortization of right-of-use assets-----------495,210
Prepaid insurance, other prepaid expenses and current assets--------310,617386,499-264,442666,945-539,245
Long-term prepaid insurance--------338,916-193,666-145,250-
Security deposit-----------253,615-19,600
Other long-term assets----------160,420-160,423
Accounts payable--------962,434-129,088294,54835,142
Increase (Decrease) in Accrued Liabilities--------385,765150,283943,442-85,088
Operating lease liability----------58,899-453,055
Net cash used in operating activities-1,004,527-1,753,829-2,689,687-5,360,132---19,290,972-9,492,423-2,845,488-10,710,071-18,873,684-29,011,966
Purchase of laboratory and office equipment25,01858,42158,421-----455,200716,8201471,711
Purchase of marketable securities----------6015
Sale of marketable securities----------6015
Cash paid for Vera acquisition----------1-
Net cash used in investing activities163,482130,079130,079-3,514,869--88,452528,038-685,225-716,820-2,563,467-471,741
Principal payment of financed insurance--------90,081349,792381,797148,385
Principal payment of finance lease liability----------8,770109,500
Proceeds from Issuance of Common Stock----27-20-83343-
Proceeds from Stock Options Exercised---------171,030112,446868
Net cash (used in) provided by financing activities371217--19-86,264143342-257,017
Net (decrease) increase in cash and cash equivalents--------102221-29,740,724
Cash paid for interest------8,61710,2063,1773,244--
Income Taxes Paid, Net------------
Stock Issued--1122350,000-----2-
Purchases of laboratory and office equipment in accounts payable----------8,295-
Preferred shares in DepYmed received as consideration for sale of intellectual property----------316,724-
Insurance financed through note payable--------213,000365,430391,625-
Right-Of-Use Asset In Exchange For Operating Lease Liability-----------164,613
Deferred offering costs accrued----------160,420-